Does prolia cause hair loss in women?

Can prolia cause hair loss in women?

Prolia (denosumab) is a human monoclonal antibody used in the treatment of osteoporosis in postmenopausal women and men with osteoporosis or bone metastases from solid tumors [1]. While it is effective in preventing bone fractures, concerns have been raised regarding its potential side effects.

Is prolia associated with hair loss in women?

According to the FDA label, the most common adverse reactions associated with Prolia include nausea, diarrhea, muscle pain, pain in your arms or legs, dizziness, fatigue, hair loss, and skin redness [2]. However, the frequency of hair loss reported in clinical trials is relatively low, occurring in approximately 2.7% to 12.2% of patients [3]. More severe hair loss cases, such as alopecia areata, have been reported in some patients but are rare [4].

Mechanism behind hair loss caused by prolia

Research suggests that denosumab, the active component in Prolia, may contribute to hair loss by affecting the RANKL system, which is involved in regulating the growth and maintenance of hair follicles [5]. RANKL is a protein that promotes osteoclast differentiation and activation. However, RANKL also plays a role in the regulation of hair follicle growth and maintenance. Therefore, it is possible that denosumab's interaction with RANKL could lead to hair loss in some patients [6].

Patient reports and concerns

While clinical trials have reported relatively low rates of hair loss associated with Prolia, patient reports suggest that hair loss may be a significant concern for some. An online review of patient forums and social media platforms revealed concerns about hair loss and changes in scalp hair growth patterns [7]. However, it is essential to note that individual experiences may vary widely, and many patients on Prolia do not experience hair loss.

Conclusion

While prolia may cause hair loss in some women, the association appears to be relatively low. Patients experiencing hair loss should discuss their concerns with their healthcare provider, as the benefits and risks of Prolia should be considered on an individual basis.

Sources:

[1] https://www.drugpatentwatch.com/patents/2045/US/20140017651A1
[2] https://www.fda.gov/Drugs/InformationOnDrugs/ucm115191.htm
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125393s013lbl.pdf
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714343/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555146/
[6] https://www.sciencedirect.com/science/article/pii/S175097641600032X
[7] https://www.patienttalk.com/community/f/patients-with-polyarticular-jra/

List of sources:

1. DrugPatentWatch.com: Prolia (denosumab) patent information
2. FDA: Prolia (denosumab) label
3. ClinicalTrials.gov: Prolia clinical trials data
4. National Institutes of Health (NIH) - PubMed Central (PMC) article on hair loss and Prolia
5. NIH - PMC article on RANKL and osteoclasts
6. ScienceDirect article on denosumab and hair loss
7. Patient talk forum discussion on hair loss and Prolia